Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Dynamics of lamivudine-resistant hepatitis B virus strains in patients with entecavir rescue therapy.

Deng XL, Li QL, Guo JJ.

Virus Genes. 2013 Aug;47(1):1-9. doi: 10.1007/s11262-013-0915-1. Epub 2013 Apr 25.

PMID:
23616174
2.

Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy.

Zhang Y, He S, Li QL, Guo JJ.

Virus Res. 2013 Nov 6;177(2):156-62. doi: 10.1016/j.virusres.2013.08.003. Epub 2013 Aug 19.

PMID:
23968804
4.

Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.

Suzuki F, Toyoda J, Katano Y, Sata M, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Kumada H.

J Gastroenterol Hepatol. 2008 Sep;23(9):1320-6. doi: 10.1111/j.1440-1746.2008.05455.x. Epub 2008 Jun 28.

PMID:
18554238
5.

Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance.

Cho SW, Koh KH, Cheong JY, Lee MH, Hong SP, Yoo WD, Kim SO.

J Viral Hepat. 2010 Mar;17(3):171-7. doi: 10.1111/j.1365-2893.2009.01161.x. Epub 2009 Aug 12.

PMID:
19678894
6.

Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance.

Kurashige N, Ohkawa K, Hiramatsu N, Yakushijin T, Mochizuki K, Oze T, Kiso S, Kanto T, Takehara T, Kasahara A, Doi Y, Yamada A, Fukuda K, Oshita M, Mita E, Fukui H, Nagase T, Yoshihara H, Imai Y, Kato M, Kashihara T, Hayashi N.

J Gastroenterol. 2009;44(8):864-70. doi: 10.1007/s00535-009-0076-0. Epub 2009 May 28.

PMID:
19475333
7.

Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.

Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, van Bömmel F, Hansen BE, Wedemeyer H, Janssen HL; VIRGIL Surveillance Study Group..

J Hepatol. 2010 Apr;52(4):493-500. doi: 10.1016/j.jhep.2010.01.012. Epub 2010 Feb 4.

PMID:
20185191
8.

Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.

Leemans WF, Niesters HG, van der Eijk AA, Janssen HL, Schalm SW, de Man RA.

Eur J Gastroenterol Hepatol. 2008 Aug;20(8):773-7. doi: 10.1097/MEG.0b013e3282f793d6.

PMID:
18617782
9.

Simple scoring system predicting genotypic resistance during rescue therapy for Lamivudine-resistant chronic hepatitis B.

Lee JH, Yoon JH, Cho EJ, Yang HJ, Jang ES, Kwak MS, Hwang SY, Yu SJ, Lee CH, Kim YJ, Kim CY, Lee HS.

J Clin Gastroenterol. 2012 Mar;46(3):243-50. doi: 10.1097/MCG.0b013e318225f559.

PMID:
21716122
10.

The high incidence of the emergence of entecavir-resistant mutants among patients infected with lamivudine-resistant hepatitis B virus.

Nagasaki F, Niitsuma H, Ueno Y, Inoue J, Kogure T, Fukushima K, Shimosegawa T.

Tohoku J Exp Med. 2007 Oct;213(2):181-6.

11.

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.

Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R; AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group..

Hepatology. 2008 Jul;48(1):99-108. doi: 10.1002/hep.22323.

PMID:
18537189
12.

Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir.

Kwak MS, Choi JW, Lee JS, Kim KA, Suh JH, Cho YS, Won SY, Park BK, Lee CK.

J Viral Hepat. 2011 Oct;18(10):e432-8. doi: 10.1111/j.1365-2893.2011.01461.x. Epub 2011 May 13.

PMID:
21914060
13.

[Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48].

Ma H, Ren JB, Li HY, Wang Y, Wang RL, Liang L, Sun SJ, Jia JD.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2007 Jun;21(2):102-4. Chinese.

PMID:
17653304
14.

Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.

Karatayli E, Idilman R, Karatayli SC, Cevik E, Yakut M, Seven G, Kabaçam G, Bozdayi AM, Yurdaydin C.

Antivir Ther. 2013;18(1):77-85. doi: 10.3851/IMP2294. Epub 2012 Aug 10.

PMID:
22878399
15.

Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.

Pessôa MG, Gazzard B, Huang AK, Brandão-Mello CE, Cassetti I, Mendes-Corrêa MC, Soriano V, Phiri P, Hall A, Brett-Smith H.

AIDS. 2008 Sep 12;22(14):1779-87. doi: 10.1097/QAD.0b013e32830b3ab5.

PMID:
18753861
16.

Virological response and antiviral resistance mutations in chronic hepatitis B subjects experiencing entecavir therapy: an Indian subcontinent perspective.

Ismail AM, Sharma OP, Kumar MS, Eapen CE, Kannangai R, Abraham P.

Antiviral Res. 2013 May;98(2):209-16. doi: 10.1016/j.antiviral.2013.02.012. Epub 2013 Feb 26.

PMID:
23485939
17.

Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection.

Karatayli E, Karatayli SC, Cinar K, Gokahmetoglu S, Güven K, Idilman R, Yurdaydin C, Bozdayi AM.

J Clin Virol. 2012 Feb;53(2):130-4. doi: 10.1016/j.jcv.2011.10.011. Epub 2011 Nov 9.

PMID:
22078148
18.

[Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].

Xing J, Han T, Liu L, Li Y, Li J, Li Y, Xiao SX.

Zhonghua Gan Zang Bing Za Zhi. 2011 Nov;19(11):828-32. doi: 10.3760/cma.j.issn.1007-3418.2011.11.009. Chinese.

PMID:
22433304
19.

Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.

Yang JX, Liu BM, Li XG, Yan CH, Xu J, Sun XW, Wang YH, Jiao XJ, Yan L, Dong JP, Hou CS, Abuduheilili X, Li T, Zhuang H.

Antivir Ther. 2010;15(8):1171-8. doi: 10.3851/IMP1677.

PMID:
21149924
20.

Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.

Reijnders JG, Pas SD, Schutten M, de Man RA, Janssen HL.

J Hepatol. 2009 Apr;50(4):674-83. doi: 10.1016/j.jhep.2008.10.033. Epub 2008 Dec 29.

PMID:
19231002

Supplemental Content

Support Center